Pathology: metastatic/advanced RCC (mRCC) - 1st line (L1); mRCC - L1 - PDL1 positive;
metastatic/advanced RCC (mRCC) - 1st line (L1) | mRCC - L1 - PDL1 positive | ||
IMmotion-150 (At - all population), 2018 | IMmotion-150 (At - PDL1>1%), 2018 | ||
atezolizumab alone | 2 | T1 | T1 |
sunitinib | 0 | T0 | T0 |